This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| 25B | |
|---|---|
| Name | 25B |
25B 25B is a substituted phenethylamine belonging to a class of synthetic psychoactive compounds derived from the phenethylamine scaffold. It has been encountered in recreational contexts, experimental pharmacology, and analytical chemistry reports, and is chemically related to a range of substituted amphetamines, substituted phenethylamines, and arylalkylamines that have been studied throughout the late 20th and early 21st centuries. The compound has been the subject of forensic identification, regulatory scheduling, and occasional case reports in clinical toxicology.
The compound is named according to systematic organic nomenclature as a 2,5-dimethoxy-4-bromo-substituted phenethylamine derivative in the family of ring-substituted phenethylamines. Synonyms used in analytical and forensic literature include positional descriptors and registry identifiers used by chemical catalogs, analytical laboratories, and databases maintained by organizations such as European Monitoring Centre for Drugs and Drug Addiction, United Nations Office on Drugs and Crime, and national forensic systems. IUPAC-style and common usage names appear alongside Chemical Abstracts Service registry numbers in seized-sample reports, and the substance is indexed in controlled-substances lists administered by authorities in countries such as United States Drug Enforcement Administration, Home Office (United Kingdom), and counterparts in Australia, Canada, and member states of the European Union.
The molecule is a benzene-ring-containing arylalkylamine with two methoxy substituents at the 2- and 5-positions and a halogen atom at the 4-position, giving it a molecular profile similar to other 2,5-dimethoxy-4-halogen phenethylamines characterized in journals like Journal of Medicinal Chemistry and European Journal of Pharmacology. Physical descriptions in forensic reports note properties such as crystalline or powder appearance, melting point ranges, and solubility characteristics referenced in spectroscopic analyses conducted by laboratories associated with National Institute of Standards and Technology, Forensic Science Service (UK), and university research groups. Analytical identification typically employs techniques and instrumentation developed in laboratories at institutions such as Massachusetts Institute of Technology, University of California, San Francisco, and national reference centers using gas chromatography–mass spectrometry, liquid chromatography–mass spectrometry, and nuclear magnetic resonance methods standardized in publications by American Chemical Society journals.
Synthetic routes reported in chemical literature and forensic reconstructions generally follow routes used for ring-substituted phenethylamines, employing precursors and reagents documented in organic synthesis texts from publishers such as Springer, Wiley, and Elsevier. Common laboratory-scale approaches involve stepwise introduction of methoxy substituents, halogenation strategies, and reductive amination steps analogous to methods described in protocols from research groups at University of Oxford, ETH Zurich, and Tokyo University. Precursors and intermediates may be traced through trade and regulatory surveillance documents from agencies like Europol and national customs services; clandestine synthesis patterns are discussed in reports by United Nations Office on Drugs and Crime and regional law-enforcement briefings.
The pharmacological profile is inferred from structure–activity relationships established for 2,5-dimethoxy-4-substituted phenethylamines in studies published in outlets such as Psychopharmacology (journal), British Journal of Pharmacology, and conference proceedings of the Society for Neuroscience. These compounds commonly interact with monoaminergic systems, particularly serotonergic receptors such as the 5-HT2A receptor and related subtypes, with downstream effects on corticolimbic circuits studied at research centers including National Institutes of Health and university neuroscience departments. Receptor-binding assays, functional studies in heterologous expression systems, and behavioral pharmacology in animal models reported by teams at Columbia University, Johns Hopkins University, and European neuroscience institutes inform mechanistic hypotheses; however, direct clinical pharmacodynamic data for this specific compound are limited.
There is no established approved therapeutic indication supported by randomized controlled trials for this compound. Investigations into related substituted phenethylamines and arylalkylamines have informed contemporary clinical research into psychedelic-assisted therapies led by institutions such as Imperial College London, Johns Hopkins Center for Psychedelic and Consciousness Research, and Multidisciplinary Association for Psychedelic Studies, but translation of findings to this specific halogenated phenethylamine has not produced approved medical uses. Case reports and toxicology series published in journals affiliated with American College of Medical Toxicology and national poison centers document acute presentations rather than therapeutic administration.
Regulatory status varies by jurisdiction and has been addressed in scheduling actions and advisory lists maintained by agencies including the United States Drug Enforcement Administration, Home Office (United Kingdom), Australian Criminal Intelligence Commission, and the European Monitoring Centre for Drugs and Drug Addiction. Many national legislatures and regulatory bodies have applied controlled-substance analog statutes, temporary class drug orders, or specific legislation targeting substituted phenethylamines to address public-health concerns, with documentation appearing in parliamentary records, regulatory gazettes, and international monitoring reports compiled by the United Nations Office on Drugs and Crime.
Safety data are limited and primarily derived from forensic case series, poison-center reports, and extrapolation from studies of structurally related compounds published in clinical toxicology outlets and emergency-medicine journals such as Annals of Emergency Medicine, Clinical Toxicology (journal), and regional toxicology bulletins. Reported acute effects in clinical encounters include sympathomimetic signs, perceptual disturbances, and neuropsychiatric symptoms necessitating supportive care in settings coordinated with institutions like hospital emergency departments and regional poison-control centers. Contraindications are inferred from pharmacology and include conditions where serotonergic agonism or sympathomimetic effects pose elevated risk, as discussed in consensus statements and clinical guidelines from professional bodies such as the American Academy of Clinical Toxicology.
Category:Phenethylamines